Stanley Capital’s Post

Over a week to go until Pharmacovigilance World 2024! 💫 Quark is excited to sponsor and exhibit at the event where attendees will discover how to leverage new tools like Quark Publishing Platform NextGen to enhance drug safety, improve patient outcomes, and meet evolving regulatory demands. Learn more about the event here 👉 https://buff.ly/3SYhFJO #Pharmacovigilance #Lifesciences #DrugSafety #RegulatedContent

By joining the #pharmacovigilance Operations #PEAKMatrix® assessment, you will spotlight your capabilities, gain visibility, and help provide a comprehensive view of the pharmacovigilance landscape. Participate: https://okt.to/fixZ3U

🚀 We are thrilled to celebrate the extraordinary contributions of our very own Jan Petracek and Marcela Fialova to the field of pharmacovigilance! 🚀 As globally recognized experts, Jan and Marcela have consistently pushed the boundaries of what’s possible in drug safety. Their latest achievement? A chapter on Spontaneous Reporting Systems in the newly released book, Principles and Practice of Pharmacovigilance and Drug Safety. In this chapter, they explore how spontaneous reporting systems—essential tools for monitoring drug safety—have evolved with advancements in technology. Their insights are invaluable for anyone working in or studying pharmacovigilance, highlighting the critical role these systems play in ensuring drug safety. We are incredibly proud of their work and its impact on the global pharmacovigilance community. Join us in celebrating this significant accomplishment and dive into their chapter to learn more about the latest advancements in drug safety. 👉 Read the chapter abstract here: https://lnkd.in/e_cZPbca #Pharmacovigilance #DrugSafety #Healthcare #IVIGEE #Expertise

Pharmacovigilance World 2024 event! Simplify your workflow and ensure compliance. Discover how Quark Publishing Platform NextGen can revolutionize your document production. Learn more and register here: https://lnkd.in/etTn5in9 #pharmacovigilance #DrugSafety #PatientOutcomes #lifesciences #regulatedcontent

By joining the #pharmacovigilance Operations #PEAKMatrix® assessment, you will spotlight your capabilities, gain visibility, and help provide a comprehensive view of the pharmacovigilance landscape. Participate: https://okt.to/SBD86m

Exciting News in Drug Safety! The FDA's Center for Drug Evaluation and Research (CDER) has launched the Emerging Drug Safety Technology Program (EDSTP), along with the Emerging Drug Safety Technology Meetings (EDSTM), set to revolutionize industry's approach to pharmacovigilance. What’s the EDSTP? The EDSTP aims to explore and implement cutting-edge technologies such as artificial intelligence and machine learning to enhance drug safety assessments. This initiative will foster better predictions, detections, and responses to drug safety issues. Introducing EDSTM: EDSTM offers a unique platform for eligible participants from the industry to engage directly with CDER. The meetings are designed to share insights on the application of AI and other technologies in pharmacovigilance, discussing both opportunities and challenges. This is a great chance for mutual learning and advancing the integration of technology in drug safety. Why It Matters: Enhanced Monitoring: Faster and more accurate detection of adverse events. Proactive Safety Measures: Improved predictive analytics for potential safety issues. Regulatory Innovation: Encourages technological collaboration and innovation in regulatory frameworks. As professionals in pharmaceuticals and healthcare, this initiative not only improves our ability to protect public health but also encourages technological collaboration. #Pharmacovigilance #DrugSafety #FDA #HealthTech #Innovation #Pharmaceuticals #PublicHealth #ArtificialIntelligence

A new survey of pharma and biotech companies reveals how pharmacovigilance outsourcing is undergoing a pivotal transformation. Watch our on-demand webinar for an exclusive first look at the research results, including: * What three PV operations are outsourced the most? * What profound outsourcing decision are 89% of pharma companies planning to implement? * And, what’s the reason more than half of biotech and pharma give for making that decision? Listen to our safety experts, Gurpreet Singh, Scott Fonseca, and Archana Hegde, for in-depth survey analysis and how their insights can help boost your operational efficiency, reduce costs, and leverage advanced technology in pharmacovigilance. Watch now: https://bit.ly/4ay0Prt #pharmacovigilance #pv #pvoutsourcing #qppv

💡 Discover Why Qinecsa – Leaders in pharmacovigilance technology! Together, we are stronger - through our advanced pharmacovigilance platforms Reportum, CVW, and now adding Insife HALOPV, Qinecsa empowers global clients, regardless of the size of operation, to capture, manage, and evaluate drug safety data with unparalleled efficiency and accuracy throughout the entire drug lifecycle. 👉 Learn about Qinecsa's acquisition of Insife and our shared strategic vision to deliver first-class services and technologies: https://lnkd.in/dX-P9hRv. 👉 Contact us to arrange a demo of our best-of-breed technologies: https://lnkd.in/dFYDuMME Qinecsa Solutions brings together best-in-class technology and scientific expertise to connect life science companies to the right safety solutions. #AdvancingDrugSafety #Pharmacovigilance #PV #DrugSafety #TrustedPartner #Reportum #CVW #HALOPV #Qinecsa

Our team is ready to dive deep into #AI, digital transformations, and automatization of pharmacovigilance processes on #WorldDrugSafetyCongress 😎 So don't forget to book a meeting!

We are at #DIA Today! Meet our leadership team member, Howard Abroms to discuss essential questions of a Drug Safety RFP #DIA24 #DIA #DrugSafety #PV #Pharmacovigilance #Caseprocessing #MedicalInformation #Soterius #REMS #SafetyDataExchange